. 2014 Nov 7;20(41):15110–15118. doi: 10.3748/wjg.v20.i41.15110

Table 1.

Pivotal phase III studies of first-line chemothrapy for advanced pancreatic cancer

Ref.	Treatment	n	ORR	PFS/TTP (mo)	MST (mo)
Burris et al[1]	GEM	63	5.4%	9 wk^b	5.65^b
Burris et al[1]	5-FU	63	0%	4 wk	4.41
Moore et al[13]	GEM	284	8%	3.55	5.91
Moore et al[13]	GEM + erlotinib	285	8.6%	3.75^d	6.24^e
Conroy et al[14]	GEM	171	9.4%	3.3	6.80
Conroy et al[14]	FOLFIRINOX	171	31.6%^d	6.4^d	11.1^d
Von Hoff et al[15]	GEM	430	7%	3.7	6.70
Von Hoff et al[15]	GEM + nab-paclitaxel	431	23%^d	5.5^d	8.50^d

P < 0.01 vs 5-FU;

P < 0.01 vs GEM;

P < 0.05 vs GEM. PFS: Progression-free survival; TTP: Time to progression; MST: Median survival time; GEM: Gemcitabine; ORR: Objective response rate; 5-FU: 5-fluorouracil; FOLFIRINOX: Oxaliplatin, irinotecan, fluorouracil and leucovorin.